Jefferies Reiterates Buy Rating on atai Life Sciences N.V (ATAI): "keen on ATAI's robust BPL-003 Phase IIb TRD results"
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $10.00 price target on atai Life Sciences N.V (NASDAQ: ATAI)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
